Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced new data demonstrating the ability of its plasma-based liquid biopsy panel for solid tumors to detect EGFR mutations in patients with non-small cell lung cancer (NSCLC) with acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs). Additionally, utilizing Exosome Diagnostics’ proprietary technology platform that co-isolates and analyzes exosomal RNA (exoRNA) and cell-free DNA (cfDNA), the panel was able to detect mutations in NSCLC patients previously characterized as negative by an external high-sensitivity PCR-based method relying on cfDNA alone.